Nuclear Mechanisms Involved in Endocrine Resistance
Author:
Open Access
- 15 September 2021
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 11
Abstract
Endocrine therapy is a standard treatment offered to patients with ERα (estrogen receptor α)-positive breast cancer. In endocrine therapy, ERα is either directly targeted by anti-estrogens or indirectly by aromatase inhibitors which cause estrogen deficiency. Resistance to these drugs (endocrine resistance) compromises the efficiency of this treatment and requires additional measures. Endocrine resistance is often caused by deregulation of the PI3K/AKT/mTOR pathway and/or cyclin-dependent kinase 4 and 6 activities allowing inhibitors of these factors to be used clinically to counteract endocrine resistance. The nuclear mechanisms involved in endocrine resistance are beginning to emerge. Exploring these mechanisms may reveal additional druggable targets, which could help to further improve patients’ outcome in an endocrine resistance setting. This review intends to summarize our current knowledge on the nuclear mechanisms linked to endocrine resistance.Keywords
This publication has 227 references indexed in Scilit:
- The estrogen-regulated anterior gradient 2 (AGR2) protein in breast cancer: a potential drug target and biomarkerBreast Cancer Research, 2013
- Reduced Expression of miR-200 Family Members Contributes to Antiestrogen Resistance in LY2 Human Breast Cancer CellsPLOS ONE, 2013
- Highly sensitive profiling of CD44+/CD24− breast cancer stem cells by combining global mRNA amplification and next generation sequencing: Evidence for a hyperactive PI3K pathwayCancer Letters, 2012
- Steroid receptor coactivators 1, 2, and 3: Critical regulators of nuclear receptor activity and steroid receptor modulator (SRM)-based cancer therapyMolecular and Cellular Endocrinology, 2012
- Cracking the Estrogen Receptor's Posttranslational Code in Breast TumorsEndocrine Reviews, 2011
- Deconstructing the molecular portraits of breast cancerMolecular Oncology, 2010
- Endocrine resistance associated with activated ErbB system in breast cancer cells is reversed by inhibiting MAPK or PI3K/Akt signaling pathwaysInternational Journal of Cancer, 2009
- The Epithelial-Mesenchymal Transition Generates Cells with Properties of Stem CellsCell, 2008
- Systemic Spread Is an Early Step in Breast CancerCancer Cell, 2008
- The pleiotropic functions of the Y‐box‐binding protein, YB‐1BioEssays, 2003